Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of urelumab with or without nivolumab in advanced malignant tumors
jRCT2080223015Phase 1
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of urelumab and nivolumab in Non-hematologic malignancy (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability of urelumab (with or without nivolumab), Pharmacokinetics of urelumab (with or without nivolumab) and 1 more.
02
Drugs
urelumabnivolumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080223015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223015.